Maria Tricarico
Sapienza University of Rome
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Maria Tricarico.
Phytochemistry | 1982
Maurizio Botta; Francesco De Angelis; Rosario Nicoletti; Maria Tricarico
Abstract Analysis of the hydrocarbon fraction from baltic amber is described. Transformations which have occurred in resins during the formation of amber are discussed on the grounds of acid-catalysed reactions undergone by 7,13-abietadiene and sclareol.
International Journal of Immunopharmacology | 1994
Stefania D'Atri; Luigina Romani; Enzo Bonmassar; Ursula Grohmann; Maria Tricarico; Stephen E. Christmas; Michael Moore
Murine tumor cells treated with triazene compounds (TZC), in vivo or in vitro, are capable of eliciting specific transplantation resistance in syngeneic hosts, and T-cell-mediated proliferative and cytotoxic responses, directed against novel drug-induced antigen(s). Since this phenomenon, referred to as chemical xenogenization (CX) could open up new perspectives in the immunochemotherapy of human neoplasias, it was of interest to investigate whether CX could also occur in human tumors. However, established human tumor cell lines along with fully immunocompetent autologous lymphocytes, are seldom available. Therefore studies were carried out to test whether parental or TZC-treated tumor cells could be differentially recognized by allogeneic lymphocytes. Experiments were performed in both human and murine models, using a lung adenocarcinoma line treated in vitro with TZC, or an established xenogenized mouse lymphoma, respectively. The results indicate that allogeneic cytotoxic T-lymphocytes (CTL) recognize specifically murine TZC-treated tumor cells. This was supported by the finding that antisera directed against the drug-treated cells abrogated the generation and the cytolytic activity of allogeneic CTL reactive against the TZC-treated tumor. In addition it was found that changes of the antigenic pattern of cell membrane recognizable by cloned allogeneic CTL occur in the TZC-treated human carcinoma cell line.
Archive | 1990
Stefania D’Atri; Lucio Tentori; Maria Tricarico; E. Bonmassar
One of the major goals of tumor immunology is the development of experimental procedures capable of enhancing responsiveness of the host to cancer.
Journal of Interferon and Cytokine Research | 2013
Ornella Franzese; Maria Tricarico; Giuseppe Starace; Rita Pepponi; Laura Bonmassar; Andrea Cottarelli; Maria Pia Fuggetta
It is well known that ionizing radiations induce a marked downregulation of antigen-dependent and natural immunity for a prolonged period of time. This is due, at least in part, to radiation-induced apoptosis of different lymphocyte subpopulations, including natural killer (NK) cells. Aim of this study was to investigate the capability of Beta Interferon (β-IFN) and Interleukin-2 (IL2), alone or in combination, to restore the functional activity of the natural immune system. Mononuclear cells (MNCs) obtained from intact or in vitro irradiated human peripheral blood were treated in vitro with β-IFN immediately before or at the end of the 4-day treatment with IL2. Time-course analysis was performed on the NK activity, the total number and the apoptotic fraction of CD16+ and CD56+ cells, the 2 main NK effector cell subpopulations. The results indicate that radiation-induced impairment of natural cytotoxicity of MNC could be successfully antagonized by the β-IFN+IL2 combination, mainly when exposure to β-IFN preceded IL2 treatment. This radioprotective effect is paralleled by lower levels of radiation-induced apoptosis and increased expression of the antiapoptotic Bcl-2 protein. Since natural immunity can play a significant role in antitumor hosts resistance, these results could provide the rational basis for a cytokine-based pharmacological strategy able to restore immune responsiveness and to afford possible therapeutic benefits in cancer patients undergoing radiotherapy.
Life Sciences | 2001
Roberto Falchetti; Maria Pia Fuggetta; Giulia Lanzilli; Maria Tricarico; Giampietro Ravagnan
International Journal of Oncology | 2006
Giulia Lanzilli; Maria Pia Fuggetta; Maria Tricarico; Andrea Cottarelli; Annalucia Serafino; Roberto Falchetti; Giampietro Ravagnan; Mario Turriziani; Riccardo Adamo; Ornella Franzese; Enzo Bonmassar
Journal of Experimental & Clinical Cancer Research | 2006
Maria Pia Fuggetta; Giulia Lanzilli; Maria Tricarico; Andrea Cottarelli; Roberto Falchetti; Giampietro Ravagnan; E. Bonmassar
Melanoma Research | 2004
Maria Pia Fuggetta; Stefania D'Atri; Giulia Lanzilli; Maria Tricarico; Elda Cannavo; Giovanna Zambruno; Roberto Falchetti; Giampiero Ravagnan
Archive | 2001
Giampietro Ravagnan; Roberto Falchetti; Giulia Lanzilli; Maria Pia Fuggetta; Maria Tricarico; Fulvio Mattivi
Immunopharmacology | 1991
Stefania D'Atri; Stefano Marini; Lucio Tentori; Maria Tricarico; Maria Pia Fuggetta; E. Bonmassar